Robert Jr. Baltera net worth and biography

Robert Baltera Biography and Net Worth

Director of Palisade Bio

Mr. Baltera is a seasoned biopharmaceutical executive, board director and Senior Advisor at Frazier Life Sciences, with more than three decades of experience spanning company leadership, corporate strategy, product development, operations, manufacturing, commercial planning and strategic transactions. He has served as Chief Executive Officer and Board Director of Cirius Therapeutics and currently serves on the Board of Directors of Inipharm. Previously, Mr. Baltera served as Chief Executive Officer of Amira Pharmaceuticals, where he helped advance the company’s pipeline and strategic collaborations prior to its sale to Bristol-Myers Squibb in 2011 for $475 million. He also previously served as Chairman of Mavupharma until its acquisition by AbbVie and served on the boards of Frazier Lifesciences Acquisition Corporation and Imago BioSciences, which was acquired by Merck. Earlier in his career, Mr. Baltera held several senior management positions during a 17-year tenure at Amgen. He brings deep expertise in guiding emerging life sciences companies through company formation, clinical development, operational execution, corporate development, financing and strategic transactions.

How do I contact Robert Jr. Baltera?: The corporate mailing address for Baltera and other Palisade Bio executives is 20271 Goldenrod Lane, Germantown MD, 20876. Palisade Bio can also be reached via phone at (858) 704-4900 and via email at [email protected]. Learn More on Robert Jr. Baltera's contact information.
Has Robert Jr. Baltera been buying or selling shares of Palisade Bio?: Robert Jr. Baltera has not been actively trading shares of Palisade Bio during the last ninety days. Learn More on Robert Jr. Baltera's trading history.
Who are Palisade Bio's active insiders?: Palisade Bio's insider roster includes Robert Baltera (Director), John Finley (CFO), Thomas Hallam (CEO), Mitchell Jones (Insider), Robert Trenschel (Director), and Donald Williams (Director). Learn More on Palisade Bio's active insiders.
Are insiders buying or selling shares of Palisade Bio?: During the last year, Palisade Bio insiders bought shares 6 times. They purchased a total of 125,000 shares worth more than $250,100.00. During the last year, insiders at the sold shares 4 times. They sold a total of 204,563 shares worth more than $420,524.61. The most recent insider tranaction occured on July, 9th when Director Robert Jr. Baltera bought 25,000 shares worth more than $49,000.00. Insiders at Palisade Bio own 0.1% of the company. Learn More about insider trades at Palisade Bio.
Information on this page was last updated on 7/9/2026.

Robert Jr. Baltera Insider Trading History at Palisade Bio

Robert Jr. Baltera Buying and Selling Activity at Palisade Bio

Palisade Bio Company Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Today's Range

Now: $1.93

$1.85

$1.96

50 Day Range

MA: $1.92

$1.68

$2.24

2 Week Range

Now: $1.93

$0.53

$2.86

Volume

3,330,603 shs

Average Volume

4,108,868 shs

Market Capitalization

$335.01 million

P/E Ratio

N/A

Dividend Yield